Ari Vanderwalde

Ari VanderWalde on Melanoma New Data on Ipilimumab and Nivolumab - The ASCO Post ascopost.com/videos/aacr-an…. So great to have had the opportunity to present #S1616 at a plenary session at #AACR2022. Link is to #ASCOPost video.

Combination Immunotherapy Clinical Trials: @arivanderw, @ivanpantic1980, @DrBenTran, and Zev A. Wainberg, MD, explored this topic in a plenary session Tuesday at #AACR22. Read a recap in AACR Meeting News: bit.ly/3KFQe1f

Patients with advanced melanoma receiving nivolumab plus ipilimumab in the second-line setting had significant improvement in progression-free survival. #AACR22 | @AACR @arivanderw ow.ly/wpkB50IKj2m

Combination #Immunotherapy Clinical Trials plenary today @AACR22 will feature a talk by @SU2C Catalyst clinical lead @arivanderw for patients with metastatic or unresectable #melanoma @west_cancer #standuptocancer progress.standuptocancer.org/catalyst?team=…

Conferences are back! (for now). #AACR2022

#mdpijpm e-Book of Special Issue "#Personalized Medicine in #Oncology" mdpi.com/journal/jpm/sp… This Special Issue book was edited by Dr. Ari VanderWalde from West Cancer Center and Research Institute

A NEW Special Issue "Precision Oncology" is guest-edited by Dr. Ari VanderWalde from West Cancer Center and Research Institute mdpi.com/si/95388 #mdpijpm via @JPM_MDPI #oncology #next-generation sequencing #clinical trials #liquid biopsy

My internet hasn’t been working right for 4 weeks and I can’t get anyone on the phone @comcast @Xfinity

Liberal arts college professor brutalizes Nazi, who has a permit. More alt-left indoctrination.

#ASCO15 Combination ipi +nivo better than ipi alone in 1st line melanoma. Likely benefit over nivo alone especially in PD-L1 low rumors.

SOFT trial practice changing- adding ovarian supp to AI better than tam alone in premen bca in dfs in those also getting chemo. #SABCS14

Second pictilisib study (OPPORTUNE) shows signal in Ki67 response but no evidence given for improvement in clinical end points. #SABCS14

FERGI trial shows no clear benefit of addition of pictilisib to fulvestrant in HR+ MBC, though interesting signal in PR+ subgroup #SABCS14